Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PACLITAXEL Cause Second primary malignancy? 317 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 317 reports of Second primary malignancy have been filed in association with PACLITAXEL (PACLITAXEL PACLITAXEL). This represents 0.4% of all adverse event reports for PACLITAXEL.

317
Reports of Second primary malignancy with PACLITAXEL
0.4%
of all PACLITAXEL reports
81
Deaths
63
Hospitalizations

How Dangerous Is Second primary malignancy From PACLITAXEL?

Of the 317 reports, 81 (25.6%) resulted in death, 63 (19.9%) required hospitalization, and 42 (13.2%) were considered life-threatening.

Is Second primary malignancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PACLITAXEL. However, 317 reports have been filed with the FAERS database.

What Other Side Effects Does PACLITAXEL Cause?

Neutropenia (4,553) Nausea (4,521) Dyspnoea (4,519) Diarrhoea (4,289) Off label use (4,075) Anaemia (3,949) Neuropathy peripheral (3,508) Malignant neoplasm progression (3,484) Fatigue (3,418) Death (3,143)

What Other Drugs Cause Second primary malignancy?

CYCLOPHOSPHAMIDE (1,247) DOXORUBICIN (1,151) VINCRISTINE (908) IMATINIB (763) PALBOCICLIB (658) RITUXIMAB (646) RUXOLITINIB (611) ETOPOSIDE (573) PREDNISONE (517) OCTREOTIDE (496)

Which PACLITAXEL Alternatives Have Lower Second primary malignancy Risk?

PACLITAXEL vs PACRITINIB PACLITAXEL vs PALBOCICLIB PACLITAXEL vs PALIPERIDONE PACLITAXEL vs PALIVIZUMAB PACLITAXEL vs PALONOSETRON

Related Pages

PACLITAXEL Full Profile All Second primary malignancy Reports All Drugs Causing Second primary malignancy PACLITAXEL Demographics